SNORD66: A Potential Drug Target for Various Diseases (G692107)

Target Name: SNORD66

NCBI ID: G692107

SNORD66

Other Name(s): HBII-142 | Small nucleolar RNA, C/D box 66 | small nucleolar RNA, C/D box 66

SNORD66: A Potential Drug Target for Various Diseases

SNORD66 (HBII-142) is a protein that is expressed in various tissues of the body, including the brain, heart, and lungs. It is a key regulator of the cell signaling pathway known as the Src/FAK-associated signaling pathway, which is involved in many cellular processes, including cell growth, differentiation, and survival.

Recent studies have identified SNORD66 as a potential drug target for the treatment of various diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. The Src/FAK-associated signaling pathway is a promising target for drug development due to its involvement in many cellular processes that are disrupted in many diseases, including cancer, neurodegenerative diseases, and autoimmune disorders.

SNORD66 is a protein that is expressed in many tissues of the body, including the brain, heart, and lungs. It is a key regulator of the cell signaling pathway known as the Src/FAK-associated signaling pathway, which is involved in many cellular processes, including cell growth, differentiation, and survival.

The Src/FAK-associated signaling pathway is a protein that is involved in many cellular processes that are disrupted in many diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. It is a signaling pathway that is activated by the Src tyrosine kinase and the Fak tyrosine kinase, which are important enzymes that are involved in the development and maintenance of tissues and organs.

SNORD66 is a key regulator of the Src/FAK-associated signaling pathway. It is a protein that is expressed in many tissues of the body, including the brain, heart, and lungs. It is involved in the regulation of many cellular processes, including cell growth, differentiation, and survival.

Studies have identified SNORD66 as a potential drug target for the treatment of various diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. The Src/FAK-associated signaling pathway is a promising target for drug development due to its involvement in many cellular processes that are disrupted in many diseases.

In conclusion, SNORD66 is a protein that is expressed in many tissues of the body, including the brain, heart, and lungs. It is a key regulator of the cell signaling pathway known as the Src/FAK-associated signaling pathway, which is involved in many cellular processes, including cell growth, differentiation, and survival. Studies have identified SNORD66 as a potential drug target for the treatment of various diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. The Src/FAK-associated signaling pathway is a promising target for drug development due to its involvement in many cellular processes that are disrupted in many diseases.

Protein Name: Small Nucleolar RNA, C/D Box 66

The "SNORD66 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about SNORD66 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets